In this issue:
Update to ESMO guidelines on the treatment of oesophageal cancer
ESMO gastric cancer living guideline
Pan-Asian adapted ESMO gastric cancer guidelines
What is the trial evidence supporting T-DXd?
TGA expands tislelizumab listing
MBS item to evaluate FGFR2b expression under review
Australian regulatory evaluation of:
zolbetuximab + CLDN18.2 assay
Second-line T-DXd and HER2 assay
European-Australasian consensus on the management of advanced GEJ cancer
Status of bemarituzumab approval in the US
ILUSTRO evaluates zolbetuximab + chemotherapy and/or immunotherapy
Therapeutics with novel mechanisms of action currently under evaluation
COVID-19 resources
Conferences & Workshops
Please login below to download this issue (PDF)